AT
GSK icon

Arlington Trust’s GSK GSK Stock Holding History

Arlington Trust’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2K Sell
328
-16
-5% -$846 ﹤0.01% 403
2026
Q1 		$19K Buy
344
+24
+8% +$1.3K ﹤0.01% 335
2025
Q4 		$15.7K Hold
320
– – ﹤0.01% 271
2025
Q3 		$13.8K Sell
320
-59
-16% -$2.31K ﹤0.01% 462
2025
Q2 		$14.6K Buy
379
+59
+18% +$2.25K ﹤0.01% 464
2025
Q1 		$12.4K Hold
320
– – ﹤0.01% 499
2024
Q4 		$10.8K Hold
320
– – ﹤0.01% 461
2024
Q3 		$13.1K Hold
320
– – ﹤0.01% 433
2024
Q2 		$12.3K Hold
320
– – ﹤0.01% 433
2024
Q1 		$13.7K Sell
320
-23
-7% -$948 ﹤0.01% 363
2023
Q4 		$12.7K Buy
+343
New +$12.3K ﹤0.01% 390

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arlington Trust's GSK Position: Q2 2026 in Review

Arlington Trust reduced its GSK (GSK) stake by 4.7% in Q2 2026, selling an estimated $846 and leaving 328 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #403.

Arlington Trust first reported a position in GSK in Q4 2023 and has held it in 11 quarters since. The position peaked at $19K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Arlington Trust held 328 shares of GSK worth $17.2K as of Q2 2026.
  • Arlington Trust sold 16 GSK shares in Q2 2026, an estimated $846.
  • GSK made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #403 holding.
  • Arlington Trust first reported a position in GSK in Q4 2023 and has held it in 11 quarters since.
  • Arlington Trust's GSK position peaked at $19K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.